Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
By establishing the precedent that recognition can precede control, the international community has created a universal ...
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...
Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage ...
Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback